Bonsity Injection

Description

Introducing Bonsity Injection, a clinically proven treatment designed to combat osteoporosis in both postmenopausal women and men with primary or hypogonadal osteoporosis. Formulated with teriparatide, a parathyroid hormone analog (PTH 1-34), Bonsity is expertly crafted for subcutaneous use, ensuring effective delivery and results.   Since its initial approval in the U.S. in 1987, Bonsity has been a trusted solution for those at high risk of fractures. It is specifically indicated for postmenopausal women experiencing osteoporosis, particularly for those who have faced challenges with other osteoporosis therapies.   Likewise, it helps increase bone mass in men with osteoporosis who are at high fracture risk or have been intolerant to alternative treatments.